University of Oxford spin-out Brainomix has secured £7m ($9.8m) to market its artificial intelligence (AI) e-Aspects software. The company said the system offers a "fast and standardised assessment of stroke patient CT scans", and helps reduce the cost of treatment. In an interview with BBC News, Dr David Williams, chief executive at Brainomex, said: "We are very excited about this new technology that will help us improve our clinical care for patients who have suffered brain The company is awaiting approval for the software from the US's Food and Drug Administration.
University of Oxford spin-out Brainomix has secured £7m ($9.8m) to market its artificial intelligence (AI) e-Aspects software. The company said the system offers a "fast and standardised assessment of stroke patient CT scans", and helps reduce the cost of treatment. Brainomix's CEO, Michalis Papadakis, said the firm would focus on expanding both its software and global footprint. The company is awaiting approval for the software from the US's Food and Drug Administration.